R&D channel feed – Endpoints News

R&D channel feed

J&J, GSK advance their PhIII IL-6 rheumatoid arthritis drug down to a busy red zone

9 years ago

Captured in a harsh spotlight, biotech unicorn Moderna names Melissa Moore as its new CSO

9 years ago

Tesaro winds up for FDA pitch as PARP rivals race to the finish line

9 years ago

Takeda will transfer 300 staffers to CRO in ongoing R&D overhaul

9 years ago

Troubled Aveo hit with another setback as investigators shutter PhII

9 years ago

Geron shares plunge as J&J assesses another setback for imetelstat

9 years ago

Celgene’s update on its big Crohn’s drug? Trust us, we’re doing fine

9 years ago

Horizon snaps up rare disease drugs, pipeline, in $800M Raptor buyout

9 years ago

Gene editing star CRISPR Therapeutics files for $90M IPO

9 years ago

Protocols: Novan downsizes its IPO; GSK floats idea for government-backed vaccine development

9 years ago

Lexicon shares surge as Sanofi touts positive PhIII for their new diabetes drug

9 years ago

J&J advances through PhII with a promising hep C triple and 100% cure rate

9 years ago

Just how confident is Arie Belldegrun about Kite's position in the turbulent CAR-T race? He's glad you asked.

9 years ago

Bluebird bio adds a key process to pioneering gene therapy as it ramps up a pivotal PhIII

9 years ago

Chrono gets a $47M round for new tech designed to quell tobacco cravings

9 years ago

Pfizer seeds diabetes upstart AnTolRx with cash and an option deal

9 years ago

Stung by patient deaths, a small Juno study points to a Goldilocks formula for CAR-T

9 years ago

GW Pharma spikes as the latest buyout rumors swirl around cannabinoid pipeline

9 years ago

The next breakthrough? MSK’s Sadelain ties up with Fate on off-the-shelf CAR-Ts

9 years ago

Celgene is squeezing the trigger on an early FDA filing for key Agios cancer drug

9 years ago

$1.9B in: Moderna blueprints $100M facility, plans to double the pipeline after a $474M megaround

9 years ago

Alzheimer’s player gets $47M, a new name and a pair of marquee board members

9 years ago

$33M in hand, Rigontec opens an office in Cambridge and sets sights on its first immuno-oncology trial

9 years ago

Allergan bags an early-stage gene therapy in $60M RetroSense buyout

9 years ago

First page Previous page 319 320 321322323 324 325 Next page Last page